FDA makes historic ruling on biosimilar insulin
Patients taking Sanofi's long-acting insulin Lantus can now access Mylan's copy drug Semglee.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
On Thursday evening, the US Food and Drug Administration (FDA) ruled that a biosimilar drug is interchangeable with the original. It is the first time ever that the agency has done this.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen gets FDA approval for new Darzalex combination
For subscribers
